Human health

PBD Biotech has been working closely with the R2D2 TB Network to set up the trial protocol for its Actiphage® tuberculosis diagnostic, and the first test kit is being dispatched.

PBD Biotech is one of the companies represented at a parliamentary reception organised by the British In Vitro Diagnostics Association (BIVDA)

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.

Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage active tuberculosis - is partnering with the Rapid Research in...

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.

Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020 and 15,000 died. There is a critical need for a non-sputum based rapid test for diagnosing TB disease.

Worldwide a quarter of a million children die of tuberculosis (TB) each year, early diagnosis would help to save their lives but most are unable to produce the sample of mucus that is needed for the current test.

Tuberculosis (TB) is the leading cause of death from an infectious disease. Although a quarter of the world’s population is thought to carry latent TB, it carries a risk of progressing to the active form of TB in around 10%...

Tuberculosis (TB) is the leading cause of death from an infectious disease. Although a quarter of the world’s population is thought to carry latent TB, it only progresses to active disease in around 10% of those infected. The reasons for...

A new blood test for tuberculosis (TB) could, for the first time, enable screening of patients at an early stage of infection.